C-EQFTPrellis Biologics
AI antibody discovery, bioprinted organoids, immune diversity
discoverydiscoveringbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EQFT
C-EQFTC-EQFTAI antibody discovery, bioprinted organoids, immune diversity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Prellis Biologics AI antibody discovery, bioprinted organoids, immune diversity
Prellis Biologics uses its EXIS platform to recapture human immune biology in 3D-printed organoids for rapid discovery of diverse antibodies. The company combines machine learning, wet lab characterization, and human immune replication to identify and optimize fully human antibody therapeutics. Its portfolio spans multiple disease areas, and the site mentions strategic collaborations including a multi-target drug discovery and development collaboration with Lilly.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Prellis Biologics — Early mechanism · Lower middle. Derived deterministically from 11 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic